Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: The β-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner

PROVIDER: PRJNA325456 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR3659180.fastq.gz	Fastqsanger.gz
	SRR3659181.fastq.gz	Fastqsanger.gz
	SRR3659172.fastq.gz	Fastqsanger.gz
	SRR3659182.fastq.gz	Fastqsanger.gz
	SRR3659173.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Targeting WNT Signaling for Improved Glioma Immunotherapy [IL13R?2-targeted CAR T cells]

Project description:Metabolic gene expression analysis to explore ICG-001’s impact on metabolic changes associated with glioma differentiation after disrupting the CBP/β-Catenin interaction by treating patient-derived GBM cell lines PBT147 and PBT030 with ICG-001 (0, 5, or 10 µM) for 24 and 72 h using Nanostring nCounter platform

2024-12-20 | GSE251930 | GEO

Targeting WNT Signaling for Improved Glioma Immunotherapy [PBT]

2024-02-15 | GSE252155 | GEO

The Î²-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner

Project description:In pediatric glioma cell lines, treatment with ICG-001 had no inhibitory effect on canonical Wnt-target genes but induced significant up regulation of various known Î²-catenin target genes in both cell lines and top 20 GO-annotations of down-regulated genes by ICG-001 were associated with biosynthetic and metabolic processes and cell cycle division processes. Pediatric cell lines were treated with ICG-001 or DMSO for 48h

2016-06-14 | E-GEOD-83266 | biostudies-arrayexpress

The β-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner

Project description:In pediatric glioma cell lines, treatment with ICG-001 had no inhibitory effect on canonical Wnt-target genes but induced significant up regulation of various known β-catenin target genes in both cell lines and top 20 GO-annotations of down-regulated genes by ICG-001 were associated with biosynthetic and metabolic processes and cell cycle division processes.

2016-06-14 | GSE83266 | GEO

RNA-seq analysis on SW480 cells treated with or without YH-620 under hypoxia

Project description:To globally assess the role of alternatively translated 63 kDa NKRF, we performed and report on RNA-seq analysis on SW480 cells treated with or without novel small molecule HIF antagonist YH-620 under hypoxia. This study provides a framework for understanding the effect of novel small molecule HIF antagonist YH-620 on downstream targets. In addition, we also performed RNA-seq analysis on SW480 cells treated with or without specific small molecule CBP/catenin antagonist ICG-001 under hypoxia.

2021-06-30 | GSE160661 | GEO

Altering cancer transcriptomes using epigenomic inhibitors [Illumina beadchip]

Project description:We have compared the genome-wide effects on the transcriptome after treatment with ICG-001 (the specific CBP inhibitor) versus C646, a compound that competes with acetyl-coA for the Lys-coA binding pocket of both CBP and p300. We found that both drugs cause large-scale changes in the transcriptome of HCT116 colon cancer cells and PANC1 pancreatic cancer cells, and reverse some tumor-specific changes in gene expression. Interestingly, although the epigenetic inhibitors affect cell cycle pathways in both the colon and pancreatic cancer cell lines, the WNT signaling pathway was affected only in the colon cancer cells. Notably, WNT target genes were similarly down-regulated after treatment of HCT116 with C646 as with ICG-001. Total RNA obtained from isolated HCT116 or PANC1 cell lines were treated with 10uM ICG-001, 10uM C646, or 0.05% DMSO and collected after 12 or 96 hours.

2015-01-07 | E-GEOD-64038 | biostudies-arrayexpress

Targeting oncogenic β-catenin/CBP activity for the treatment of head and neck squamous cell carcinoma

Project description:Head and neck squamous cell carcinoma (HNSCC) presents primarily as oral squamous cell carcinoma (OSCC), an aggressive malignancy characterized by heterogeneity, locoregional metastases and resistance to existing treatments. Although a number of molecular alterations associated with OSCC have been identified, they have had limited impact on clinical management. A frequent feature of OSCC is the inappropriate activation of nuclear β-catenin. Here, we provide a comprehensive characterization of the effects of blocking the interaction between nuclear β-catenin and the cAMP-responsive element binding (CREB)-binding protein (CBP) using the small molecule inhibitor ICG-001. We demonstrate that ICG-001 inhibits cell proliferation and aggressive OSCC cell phenotypes in cellular, zebrafish and murine models, and that its inhibition-associated transcriptional signature tracks with advanced tumor grade and poor survival in human patients. Our results suggest that targeting the β-catenin/CBP interaction in the nucleus represents a new and effective therapy for OSCC.

2018-07-03 | GSE95704 | GEO

Human conjunctival fibroblasts-LC-MS/MS

Project description:The underlying mechanisms of conjunctival fibrosis are complex and involve multiple factors and signaling pathway. Wnt/β-catenin signaling pathway plays an important role in organelle fibrosis. In this study, ICG-001 that inhibiting Wnt/β-catenin pathway has been applied in TGFβ1-induced fibrosis model of primary human conjunctival fibroblasts (HConFs). To verify the regulator of TGFβ1-induced conjunctival fibrosis, 4D DIA technology and proteomics analysis were used to identify the differentially expressed genes and the enrichment KEGG pathways.

2024-05-13 | PXD051023 | Pride

Altering cancer transcriptomes using epigenomic inhibitors [RNA-Seq]

Project description:We have compared the genome-wide effects on the transcriptome after treatment with ICG-001 (the specific CBP inhibitor) versus C646, a compound that competes with acetyl-coA for the Lys-coA binding pocket of both CBP and p300. We found that both drugs cause large-scale changes in the transcriptome of HCT116 colon cancer cells and PANC1 pancreatic cancer cells, and reverse some tumor-specific changes in gene expression. Interestingly, although the epigenetic inhibitors affect cell cycle pathways in both the colon and pancreatic cancer cell lines, the WNT signaling pathway was affected only in the colon cancer cells. Notably, WNT target genes were similarly down-regulated after treatment of HCT116 with C646 as with ICG-001. To identify genes affected by direct targeting of a component of the transcriptional complex implicated in WNT regulation, we used siRNAs to knockdown TCF7L2 in PANC1 cells. Cells were treated with control siRNAs or siRNAs specific for TCF7L2 and RNA was analyzed by RNA-seq.

2015-01-07 | E-GEOD-63776 | biostudies-arrayexpress

Altering cancer transcriptomes using epigenomic inhibitors [Illumina beadchip]

2015-01-07 | GSE64038 | GEO